Novel Therapies in Breast and Gynecological Cancers
Our research interests center on the clinical application of novel therapies - including epidermal growth factor receptor (EGFR) inhibitors, angiogenesis inhibitors, novel cytotoxic therapies, and hormonal agents - in breast and gynecological cancers. The EGFR superfamily is an attractive therapeutic target because it is commonly overexpressed in women's cancers, it regulates vital cellular processes, and it seems to be a negative prognostic indicator. Clinical trials focusing on novel therapies for breast, ovarian, and endometrial cancer are an important area of our research. Past trials have included (1) a comparison of exemestane versus anastrozole in postmenopausal women, (2) the role of D-99 and Herceptin in the management of metastatic breast cancer, (3) the role of CI-1033 given alone in advanced ovarian cancer, and (4) the role of CI-1033 in the management of advanced breast cancer. Current active trials include (1) the role of oral irinotecan in metastatic breast cancer, (2) a phase I trial of DOXIL/ Iressa in patients with gynecological malignancies and metastatic breast cancer, and (3) a retrospective review of newly diagnosed premenopausal women with endometrial cancer. Current projects include the establishment of a research program in endometrial cancer with specific attention to the adjuvant management of high-risk and metastatic disease. We are exploring ideas that include the role of aromatase inhibitors and Cox 2 inhibitors in the management of advanced endometrial cancer, the role of three-drug combinations as adjuvant therapy in the management of endometrial cancer, and the role of anti-VEGF molecules with cytotoxic therapy in advanced gynecological malignancies. Other research interests include the adjuvant management of advanced and poor histological types of endometrial cancer, new agents for metastatic endometrial cancers, and an epidemiological study of young premenopausal women with endometrial cancer.